Wednesday, February 1, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

Killing Ebola by Removing Its Coat

by Global Biodefense Staff
April 17, 2015
Ebola Protein Coating Research VP35
A protein — shown in red, white and blue — typically coats the genome of the Ebola virus, providing protection from enzymes that can destroy the virus’s genetic material.

Scientists at Washington University School of Medicine in St. Louis have found that a protein made by the Ebolavirus removes a protective coat from the virus’s genetic material, exposing the viral genome so that it can be copied, and then returns the coat.

Simply interfering with this process appears to kill the virus.

The researchers introduced proteins into Ebola-infected cells, which carried a short chain of amino acids that forms the part of the protein that removes the coat. But they lacked the ability to return the coating, disrupting the emergence of newly created viruses from infected cells. Consequently, the virus did not survive.

“This coat-check protein, known as VP35, has a great deal of potential as a new target for Ebola treatments,” said senior author Gaya Amarasinghe, PhD, assistant professor of pathology and immunology at the School of Medicine. “If we can block this process, we can stop Ebola infection by blocking viral replication.”

The study appears April 9 in Cell Reports.

“One of the major challenges was that the part of VP35 involved in this interaction is an intrinsically disordered peptide,” said Leung, an assistant professor of pathology and immunology at Washington University. “This means that it may not take on a definite structure until it binds to another protein. That made structural studies of VP35 difficult because the structure, which plays a critical role in determining function, doesn’t form without its specific binding partner.”

The researchers showed that VP35 binds to the virus’s nucleoprotein — which forms part of the protective coat worn by the virus’ RNA. They found that this binding removes the nucleoprotein from the viral RNA prior to replication. And while the viral RNA is being copied, VP35 keeps newly synthesized nucleoproteins from attaching to other RNA in the host cell.

New copies of the virus require new protein coats. So VP35 also ensures that new nucleoproteins — made by the host cell’s protein-making machinery — bind only to Ebola RNA, allowing the virus to complete replicating. Disabling or disrupting VP35 could stop the virus in its tracks, according to Amarasinghe.

The research was supported by grants from the U.S. Department of Defense; Defense Threat Reduction Agency; National Institutes of Health (NIH); National Institute of General Medical Sciences; and the Center for Structural Genomics of Infectious Diseases.

Read the study at Cell Reports: An intrinsically disordered peptide from Ebola virus VP35 controls viral RNA synthesis by modulating nucleoprotein-RNA interactions.

Image credit: Amarasinghe Lab

Tags: Ebola

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC